West Oak Capital LLC Sells 200 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

West Oak Capital LLC lessened its holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 28.6% during the third quarter, Holdings Channel reports. The fund owned 500 shares of the medical instruments supplier’s stock after selling 200 shares during the period. West Oak Capital LLC’s holdings in LeMaitre Vascular were worth $46,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in the business. Shaker Investments LLC OH grew its position in shares of LeMaitre Vascular by 1.3% in the second quarter. Shaker Investments LLC OH now owns 13,833 shares of the medical instruments supplier’s stock valued at $1,138,000 after purchasing an additional 175 shares during the last quarter. NBC Securities Inc. grew its position in LeMaitre Vascular by 73.2% during the third quarter. NBC Securities Inc. now owns 433 shares of the medical instruments supplier’s stock worth $40,000 after buying an additional 183 shares in the last quarter. GAMMA Investing LLC grew its holdings in shares of LeMaitre Vascular by 34.3% during the 3rd quarter. GAMMA Investing LLC now owns 736 shares of the medical instruments supplier’s stock worth $68,000 after purchasing an additional 188 shares in the last quarter. nVerses Capital LLC increased its holdings in LeMaitre Vascular by 33.3% in the 2nd quarter. nVerses Capital LLC now owns 800 shares of the medical instruments supplier’s stock valued at $66,000 after buying an additional 200 shares during the period. Finally, Albion Financial Group UT raised its position in LeMaitre Vascular by 5.6% during the first quarter. Albion Financial Group UT now owns 3,974 shares of the medical instruments supplier’s stock valued at $264,000 after purchasing an additional 212 shares in the last quarter. Institutional investors and hedge funds own 84.64% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have issued reports on the company. Barrington Research reiterated an “outperform” rating and issued a $92.00 target price on shares of LeMaitre Vascular in a research report on Friday, September 20th. StockNews.com lowered shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Tuesday, August 27th. Lake Street Capital began coverage on shares of LeMaitre Vascular in a research note on Friday, August 2nd. They issued a “buy” rating and a $105.00 price objective for the company. Cantor Fitzgerald assumed coverage on shares of LeMaitre Vascular in a research note on Tuesday. They set a “neutral” rating and a $96.00 target price on the stock. Finally, JMP Securities upped their price target on shares of LeMaitre Vascular from $77.00 to $100.00 and gave the stock a “market outperform” rating in a report on Tuesday, August 20th. Three analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $94.67.

LeMaitre Vascular Stock Performance

LMAT stock opened at $89.88 on Friday. The company has a market capitalization of $2.02 billion, a P/E ratio of 59.52, a PEG ratio of 2.45 and a beta of 0.88. The company has a fifty day moving average price of $88.90 and a 200-day moving average price of $81.35. LeMaitre Vascular, Inc. has a 52-week low of $44.27 and a 52-week high of $93.32.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings data on Thursday, August 1st. The medical instruments supplier reported $0.52 earnings per share for the quarter, beating analysts’ consensus estimates of $0.47 by $0.05. The business had revenue of $55.85 million during the quarter, compared to the consensus estimate of $54.98 million. LeMaitre Vascular had a return on equity of 12.41% and a net margin of 18.33%. LeMaitre Vascular’s quarterly revenue was up 11.4% on a year-over-year basis. During the same period in the prior year, the business posted $0.37 earnings per share. As a group, sell-side analysts forecast that LeMaitre Vascular, Inc. will post 1.85 earnings per share for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, August 29th. Investors of record on Thursday, August 15th were paid a $0.16 dividend. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.71%. The ex-dividend date of this dividend was Thursday, August 15th. LeMaitre Vascular’s dividend payout ratio is currently 42.38%.

Insider Activity at LeMaitre Vascular

In other LeMaitre Vascular news, Director David B. Roberts sold 3,063 shares of the firm’s stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $82.07, for a total transaction of $251,380.41. Following the completion of the transaction, the director now owns 14,114 shares in the company, valued at approximately $1,158,335.98. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 10.79% of the stock is currently owned by company insiders.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.